Showing posts with label cooling cap. Show all posts
Showing posts with label cooling cap. Show all posts

Thursday, July 3, 2014

New Clinical Trial By US Oncology Research Tests Chemotherapy-Induced Hair Loss Therapy

US Oncology Research, one of the leading community-based cancer research networks in America based in The Woodlands, Texas, and Baylor College of Medicine, have launched a clinical trial titled “Scalp Cooling Alopecia Prevention Trial” (SCALP), which will examine an existing scalp cooling system aiming to critically reduce or completely stop chemotherapy-related hair loss, which occurs in about 65% of cancer patients undergoing chemotherapy and is one of the most disturbing and stressful factors in cancer patient care.

So far, a total of 15 patients have registered and approximately 50 more are being recruited at three US Oncology Research sites: Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, led by Cynthia Osborne, M.D.; Texas Oncology-Memorial City, Houston, Texas, led by Frankie Ann Holmes, M.D., and Hematology-Oncology Associates of Northern New Jersey, P.A., Morristown, N.J., led by Steven Papish, M.D., F.A.C.P.

Newly diagnosed female patients (18 years or older) with stage 1-2 breast cancer planning to undergo at least 4 cycles of full-dose anthracycline or taxane neoadjuvant or adjuvant chemotherapy are encouraged to contact one of these three participating centers for more information.

Here is the link for the trial and contact information for recruiting:
http://clinicaltrials.gov/show/NCT01986140

Tuesday, March 4, 2014

Clinical Trial to Research Breast Cancer Hair Loss Prevention

Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine are recruiting newly diagnosed breast cancer patients to participate in a new clinical trial testing the safety and efficacy of an investigational scalp cooling device to prevent hair loss associated with chemotherapy.

Participants interested in enrolling in the study must:
  • Have a new diagnosis of breast cancer stage 1 or 2 and under the age of 70
  • Plan to undergo neoadjuvant or adjuvant chemotherapy with curative intent

  • Chemotherapy must be planned for at least four cycles of full-dose anthracycline or taxane based chemotherapy regimen, defined as one of the following chemotherapy regimens:
  • Adriamycin 60mg/m2 with cyclophosphamide 600mg/m2
  • Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2
  • Paclitaxel 80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3 weeks as a single agent
  • Docetaxel 100mg/m2 as a single agent
  • Docetaxel 75mg/m2 with cyclophosphamide 600mg/m2
  • Docetaxel 75mg/m2 with carboplatin AUC of 6 and traztuzumab at standard doses

  • Study participants will be followed until 2-4 weeks after completion of chemotherapy when the final alopecia (hair loss) assessment will occur and the questionnaires will be administered. For more information or to enroll, please call Afife Batarse at 713-798-1911.

    We are hopeful that there will be a breakthrough in preventing hair loss for cancer patients in the near future.  In the meantime, our team at Ricky Knowles Hair & Wellness specializes in creating a private and supportive environment for our clients.  If you are looking for a hair duplication solution while you are undergoing cancer treatment, please call us at 713-623-4247.